Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients
Thrombosis and Haemostasis · 2023-04 · 123 (04) · 402-414
DOI: 10.1055/a-1981-1763 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 09.01.2023. Verfasst von Geoffrey Foulon-Pinto und 15 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, INSERM UMR-S-1140, Innovations Thérapeutiques en Hémostase, Paris, France. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Conny-Maeva Charitable Foundation.
Abstract (Originalsprache)
Background
Although a growing number of very elderly patients with atrial fibrillation (AF), multiple conditions, and polypharmacy receive direct oral anticoagulants (DOACs), few studies specifically investigated both apixaban/rivaroxaban pharmacokinetics and pharmacodynamics in such patients.
Aims
To investigate: (1) DOAC concentration–time profiles; (2) thrombin generation (TG); and (3) clinical outcomes 6 months after inclusion in very elderly AF in-patients receiving rivaroxaban or apixaban.
Methods
Adage-NCT02464488 was an academic prospective exploratory multicenter study, enrolling AF in-patients aged ≥80 years, receiving DOAC for at least 4 days. Each patient had one to five blood samples at different time points over 20 days. DOAC concentrations were determined using chromogenic assays. TG was investigated using ST-Genesia (STG-ThromboScreen, STG-DrugScreen).
Results
We included 215 patients (women 71.1%, mean age: 87 ± 4 years), 104 rivaroxaban and 111 apixaban, and 79.5% receiving reduced-dose regimen. We observed important inter-individual variabilities (coefficient of variation) whatever the regimen, at C max [49–46%] and C min [75–61%] in 15 mg rivaroxaban and 2.5 mg apixaban patients, respectively. The dose regimen was associated with C max and C min plasma concentrations in apixaban (p = 0.0058 and p = 0.0222, respectively), but not in rivaroxaban samples (multivariate analysis). Moreover, substantial variability of thrombin peak height (STG-ThromboScreen) was noticed at a given plasma concentration for both xabans, suggesting an impact of the underlying coagulation status on TG in elderly in-patients. After 6-month follow-up, major bleeding/thromboembolic event/death rates were 6.7%/1.0%/17.3% in rivaroxaban and 5.4%/3.6%/18.9% in apixaban patients, respectively.
Conclusion
Our study provides original data in very elderly patients receiving DOAC in a real-life setting, showing great inter-individual variability in plasma concentrations and TG parameters. Further research is needed to understand the potential clinical impact of these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, INSERM UMR-S-1140, Innovations Thérapeutiques en Hémostase, Paris, France.
- Service d'Hématologie Biologique, AP-HP. Université Paris Cité, Hôpital Lariboisière, Paris, France.
- Service de gériatrie à orientation cardiologique et neurologique, AP-HP, Sorbonne Université, Hôpitaux universitaires Pitié-Salpêtrière-Charles Foix, Ivry-sur-Seine, France.
- CEpiA Team (Clinical Epidemiology and Ageing), Université Paris Est Créteil, INSERM, IMRB, Créteil, France.
- Research Center, Institut de Cardiologie de Montréal - Université de Montréal, Montréal, QC, Canada.
- Service de Gériatrie, AP-HP. Université Paris Cité, Hôpital Européen Georges Pompidou, Paris, France.
ORCID-Profile: François Mullier, Virginie Siguret
Förderung
- Conny-Maeva Charitable Foundation
Zitieren
APA
Foulon-Pinto, G., Lafuente-Lafuente, C., Jourdi, G., Guen, J. L., Tall, F., Puymirat, E., Delrue, M., Rivière, L., Ketz, F., Gouin-Thibault, I., Mullier, F., Gaussem, P., Pautas, E., Lecompte, T., Curis, E., & Siguret, V. (2023). Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients. Thrombosis and Haemostasis, 123(04), 402-414. https://doi.org/10.1055/a-1981-1763
Vancouver
Foulon-Pinto G, Lafuente-Lafuente C, Jourdi G, Guen JL, Tall F, Puymirat E, et al. Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients. Thrombosis and Haemostasis. 2023;123(04):402-414. doi:10.1055/a-1981-1763
BibTeX
@article{FoulonPinto2023,
author = {Foulon-Pinto, Geoffrey and Lafuente-Lafuente, Carmelo and Jourdi, Georges and Guen, Julien Le and Tall, Fatoumata and Puymirat, Etienne and Delrue, Maxime and Rivière, Léa and Ketz, Flora and Gouin-Thibault, Isabelle and Mullier, François and Gaussem, Pascale and Pautas, Eric and Lecompte, Thomas and Curis, Emmanuel and Siguret, Virginie},
title = {Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients},
journal = {Thrombosis and Haemostasis},
year = {2023},
volume = {123},
number = {04},
pages = {402--414},
doi = {10.1055/a-1981-1763}
}
EUVIMED